IMM-101

BIOLOGICAL8 trials

Sponsors

AIO-Studien gGmbH, Immodulon Therapeutics Ltd, Impatients N.V. trading as myTomorrows, Canadian Cancer Trials Group, AIO-Studien-gGmbH

Conditions

Advanced Pancreatic CancerCancerColorectal CancerCovid-19Malignant MelanomaMelanomaMetastatic CancerPancreas Cancer

Phase 1

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

TerminatedNCT01559818

Immodulon Therapeutics LtdMalignant Melanoma

Start: 2012-02-29End: 2019-07-31Updated: 2023-06-22

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

TerminatedNCT03009058

Immodulon Therapeutics LtdMetastatic Cancer

Start: 2017-05-31End: 2017-08-30Updated: 2024-11-25

Phase 2

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

CompletedNCT01303172

Immodulon Therapeutics LtdAdvanced Pancreatic Cancer

Start: 2011-06-30End: 2016-01-31Updated: 2021-11-10

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

CompletedNCT03711188

Immodulon Therapeutics LtdMelanoma

Start: 2018-10-04End: 2021-12-02Updated: 2024-04-29

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruitingNCT05118724

AIO-Studien-gGmbHColorectal Cancer

Start: 2021-12-10End: 2027-04-30Target: 80Updated: 2025-06-15

Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study (ANTONIO)

Active, not recruitingCTIS2024-515224-37-00

AIO-Studien gGmbHPatients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study)

Start: 2023-08-29Target: 80Updated: 2025-11-13

Phase 3

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

CompletedNCT04442048

Canadian Cancer Trials GroupCancer, Covid-19

Start: 2020-10-01End: 2025-12-22Updated: 2025-12-30

Unknown Phase

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Impatients N.V. trading as myTomorrowsPancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage III +1

Updated: 2020-08-14

Related Papers

A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.

Journal of Clinical Oncology2022-06-01

A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.

Journal of Clinical Oncology2017-05-20

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

2016-09-0643 citations

Long term survival in IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.

Journal of Clinical Oncology2015-05-205 citations

A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.

Journal of Clinical Oncology2015-01-209 citations